Since we have detected potentially actionable PV/LPV for PARP inhibitor therapy in BRIP1 and RAD51C genes, the final percentage of actionable detected PV/LPV with germline genotyping was 66.6% (28/42), and with tumor genotyping 97.6% (41/42) (Scheme 1 and Scheme 2). This evidence concerns the gene RAD51C and neoplasm.